Cargando…

Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies

Cardiovascular events remain a substantial global health concern, necessitating innovative strategies for prevention. This study aims to assess the potential impact of influenza vaccination on major cardiovascular events. A search of the medical English literature was conducted using PubMed/MEDLINE,...

Descripción completa

Detalles Bibliográficos
Autores principales: Omidi, Fatemeh, Zangiabadian, Moein, Shahidi Bonjar, Amir Hashem, Nasiri, Mohammad Javad, Sarmastzadeh, Tala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658159/
https://www.ncbi.nlm.nih.gov/pubmed/37981651
http://dx.doi.org/10.1038/s41598-023-47690-9
_version_ 1785148217146474496
author Omidi, Fatemeh
Zangiabadian, Moein
Shahidi Bonjar, Amir Hashem
Nasiri, Mohammad Javad
Sarmastzadeh, Tala
author_facet Omidi, Fatemeh
Zangiabadian, Moein
Shahidi Bonjar, Amir Hashem
Nasiri, Mohammad Javad
Sarmastzadeh, Tala
author_sort Omidi, Fatemeh
collection PubMed
description Cardiovascular events remain a substantial global health concern, necessitating innovative strategies for prevention. This study aims to assess the potential impact of influenza vaccination on major cardiovascular events. A search of the medical English literature was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL up to 1 August 2023. Meta-analysis and stratified analyses were performed to investigate specific outcomes, including myocardial infarction (MI), cardiovascular death, and stroke. Pooled relative risks (RR) along with their 95% confidence intervals (CI) were calculated to evaluate the associations. A comprehensive analysis was conducted on a total of 9059 patients, with 4529 patients receiving the influenza vaccine and 4530 patients receiving a placebo. Among patients who received the influenza vaccine, a notable reduction in the occurrence of major cardiovascular events was observed, with 517 cases compared to 621 cases in the placebo group (RR 0.70; 95% CI 0.55–0.91). The stratified analysis revealed a decreased risk of MI in vaccinated patients (RR 0.74; 95% CI 0.56–0.97) and a significant reduction in cardiovascular death events (RR 0.67; 95% CI 0.45–0.98). This study provides compelling evidence that influenza vaccination is associated with a decreased risk of major cardiovascular events, particularly myocardial infarction, and cardiovascular death. These findings highlight the potential of influenza vaccination as an adjunctive strategy in cardiovascular disease prevention. Further research and exploration of underlying mechanisms are warranted to elucidate the observed beneficial effects.
format Online
Article
Text
id pubmed-10658159
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106581592023-11-19 Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies Omidi, Fatemeh Zangiabadian, Moein Shahidi Bonjar, Amir Hashem Nasiri, Mohammad Javad Sarmastzadeh, Tala Sci Rep Article Cardiovascular events remain a substantial global health concern, necessitating innovative strategies for prevention. This study aims to assess the potential impact of influenza vaccination on major cardiovascular events. A search of the medical English literature was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL up to 1 August 2023. Meta-analysis and stratified analyses were performed to investigate specific outcomes, including myocardial infarction (MI), cardiovascular death, and stroke. Pooled relative risks (RR) along with their 95% confidence intervals (CI) were calculated to evaluate the associations. A comprehensive analysis was conducted on a total of 9059 patients, with 4529 patients receiving the influenza vaccine and 4530 patients receiving a placebo. Among patients who received the influenza vaccine, a notable reduction in the occurrence of major cardiovascular events was observed, with 517 cases compared to 621 cases in the placebo group (RR 0.70; 95% CI 0.55–0.91). The stratified analysis revealed a decreased risk of MI in vaccinated patients (RR 0.74; 95% CI 0.56–0.97) and a significant reduction in cardiovascular death events (RR 0.67; 95% CI 0.45–0.98). This study provides compelling evidence that influenza vaccination is associated with a decreased risk of major cardiovascular events, particularly myocardial infarction, and cardiovascular death. These findings highlight the potential of influenza vaccination as an adjunctive strategy in cardiovascular disease prevention. Further research and exploration of underlying mechanisms are warranted to elucidate the observed beneficial effects. Nature Publishing Group UK 2023-11-19 /pmc/articles/PMC10658159/ /pubmed/37981651 http://dx.doi.org/10.1038/s41598-023-47690-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Omidi, Fatemeh
Zangiabadian, Moein
Shahidi Bonjar, Amir Hashem
Nasiri, Mohammad Javad
Sarmastzadeh, Tala
Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
title Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
title_full Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
title_fullStr Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
title_full_unstemmed Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
title_short Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
title_sort influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658159/
https://www.ncbi.nlm.nih.gov/pubmed/37981651
http://dx.doi.org/10.1038/s41598-023-47690-9
work_keys_str_mv AT omidifatemeh influenzavaccinationandmajorcardiovascularriskasystematicreviewandmetaanalysisofclinicaltrialsstudies
AT zangiabadianmoein influenzavaccinationandmajorcardiovascularriskasystematicreviewandmetaanalysisofclinicaltrialsstudies
AT shahidibonjaramirhashem influenzavaccinationandmajorcardiovascularriskasystematicreviewandmetaanalysisofclinicaltrialsstudies
AT nasirimohammadjavad influenzavaccinationandmajorcardiovascularriskasystematicreviewandmetaanalysisofclinicaltrialsstudies
AT sarmastzadehtala influenzavaccinationandmajorcardiovascularriskasystematicreviewandmetaanalysisofclinicaltrialsstudies